Telemedicine, Cannabis, and Prescription Platforms
Cannabis telemedicine prescribing has transformed patient access to cannabis treatments. This shift introduces challenges in clinical care and regulatory oversight. Providers must carefully evaluate telemedicine cannabis platforms to ensure safe…
THC Gummies and Drinks Face Ban Under Government Spending Bill
The hemp-derived THC products ban will affect availability of unregulated intoxicating substances. Clinicians must understand this regulatory change for patient counseling. This ban impacts hemp-derived THC products and clinical oversight.
Cannabis Extracts Significantly Reduce Myofascial Pain – Labroots
Cannabis extracts myofascial pain relief is gaining attention for its potential benefits. Emerging evidence shows THC and CBD combinations may reduce pain and improve function. This offers hope for patients with refractory myofascial pain.
2026 Cannabis Adolescent Brain Vulnerability and Risks
2026 cannabis adolescent brain vulnerability is a growing concern among researchers. Studies link teen cannabis use to increased psychiatric risks such as psychosis and depression. Understanding these risks is critical for public health and clinical…
Regulatory Digest: Cannabis Manufacturing Compliance & Rescheduling
Regulatory cannabis manufacturing compliance is evolving with recent rescheduling updates that impact clinical research. These changes aim to standardize pharmaceutical cannabis production. Understanding these regulations is key for advancing cannabis…
Cannabis Cognitive Aging Older Adults: New Insights 2026
Recent studies on cannabis cognitive aging older adults provide reassuring data about cognitive decline risks. Evidence shows THC blood levels poorly predict driving impairment. Patient access remains a critical issue in the U.S. and U.K. healthcare…
In the Mix: 9 More Cannabis Articles — March 05, 2026
This digest presents cannabis clinical research updates 2026 with 9 articles reviewed and scored below the clinical relevance threshold. Topics include policy, safety, and anxiety research. Each article summary provides insights and source links for…
Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply
Oklahoma medical cannabis regulations face scrutiny as the state considers rolling back its permissive program. Patients relying on medical cannabis should stay informed about potential changes that could disrupt treatment. Regulatory challenges…
The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
Cannabinoid research barriers in the U.S. create challenges for developing evidence-based cannabis medicines. Federal scheduling under the Controlled Substances Act fragments the regulatory environment. This limits patient access to clinically validated…
Use of Medical Marijuana or Hemp Doesn’t Excuse Drug Testing Violations
2026 cannabis federal workplace regulations clarify that medical marijuana or hemp use does not exempt employees from drug testing violations. Patients using medical cannabis may still face employment consequences despite state legalization. Clinicians…
